Kripthonite Therapeutics ApS: Financial statements 2023
CVR: 43770209
Source: annual report 2023, Danish Business Authority
10/01/2023 – 31/12/2023
Kripthonite Therapeutics ApS (CVR 43770209) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 541,641 and a net result of DKK -5,407. Equity in the 2023 report amounted to DKK 34,593. The solvency ratio was 46%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 541,641
- Profit/Loss
- DKK -5,407
- Equity
- DKK 34,593
- Total Assets
- DKK 75,122
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of January 10, 2023, Revisionsfirmaet Tom Sønderup I/S has been appointed auditor of Kripthonite Therapeutics ApS.
As of January 10, 2023, Peter Horn Møller has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Thomas Bjørnskov Poulsen has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Kristian Mark Jacobsen has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Per Hjerrild has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Erik Vinther is registered as director of Kripthonite Therapeutics ApS.
Kripthonite Therapeutics ApS was founded on January 10, 2023.
About Kripthonite Therapeutics ApS
Kripthonite Therapeutics ApS is a Danish company of the type Anpartsselskab based in Aarhus N, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Stenvang. The board consists of Søren Bregenholt Frederiksen (chair), Erik Vinther, Kristian Mark Jacobsen and Per Hjerrild. The company's owners include Marigold Innovation ApS, Thomas B. Poulsen Holding ApS and Hjerrild Chemistry Consulting ApS. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK -3,512,912 and a net result of DKK -3,936,274 compared with DKK -32 the year before. Equity in the 2025 report amounted to DKK 4,598,287.